试用视觉搜索
使用图片进行搜索，而不限于文本
你提供的照片可能用于改善必应图片处理服务。
隐私策略
|
使用条款
在此处拖动一张或多张图像或
浏览
在此处放置图像
或
粘贴图像或 URL
拍照
单击示例图片试一试
了解更多
要使用可视化搜索，请在浏览器中启用相机
English
全部
图片
灵感
创建
集合
视频
地图
资讯
购物
更多
航班
旅游
酒店
搜索
笔记本
自动播放所有 GIF
在这里更改自动播放及其他图像设置
自动播放所有 GIF
拨动开关以打开
自动播放 GIF
图片尺寸
全部
小
中
大
特大
至少... *
自定义宽度
x
自定义高度
像素
请为宽度和高度输入一个数字
颜色
全部
彩色
黑白
类型
全部
照片
插图
素描
动画 GIF
透明
版式
全部
方形
横版
竖版
人物
全部
脸部特写
半身像
日期
全部
过去 24 小时
过去一周
过去一个月
去年
授权
全部
所有创作共用
公共领域
免费分享和使用
在商业上免费分享和使用
免费修改、分享和使用
在商业上免费修改、分享和使用
详细了解
重置
安全搜索:
中等
严格
中等（默认）
关闭
筛选器
1280×720
www.ophthalmologytimes.com
EyePoint doses first patient in second global Phase 3 LUCIA clinical trial of Duravyu for the ...
3198×1734
www.ophthalmologytimes.com
AAO: Janssen announces late-breaking data from a pair of gene therapy programs
3332×1850
www.ophthalmologytimes.com
Cencora to acquire Retina Consultants of America for upwards of $5.1 Billion
1272×708
www.ophthalmologytimes.com
EyeBio announces positive data from first-in-human Ph1b/2a AMARONE tri…
1252×702
www.ophthalmologytimes.com
Exploring electrical stimulation therapy: A promising approach to vision loss i…
1200×801
www.ophthalmologytimes.com
Virtual Vision Health to unveil new features for virtual field he…
2546×846
www.ophthalmologytimes.com
FDA gives IND clearance to OKYO Pharma for OK-101 in neuropathic corneal pain
2526×1396
www.ophthalmologytimes.com
FDA gives IND clearance to OKYO Pharma for OK-101 in neuropathic corneal pain
1920×1080
www.ophthalmologytimes.com
EyePoint Pharmaceuticals announces positive topline data from Phase 2 DAVIO 2 trial of EYP-1901 ...
1920×1080
www.ophthalmologytimes.com
Regeneron announces aflibercept 8mg injection meets primary endpoint in phase 3 QUASAR trial in ...
1280×720
www.ophthalmologytimes.com
Orasis Pharmaceuticals completes $78 million financing to support commercial launch of Qlosi
1920×1080
www.ophthalmologytimes.com
ASCRS 2024: What advancements in Light Adjustable Lens technology mean for clinicians …
2524×1422
www.ophthalmologytimes.com
The FDA issues warning letters to 8 companies for manufacturing/marketing unapproved ophthalmi…
1668×929
www.ophthalmologytimes.com
OKYO Pharma announces final patient in OK-101 trial for dry eye disease complete…
1200×800
www.ophthalmologytimes.com
OKYO Pharma announces final patient in OK-101 trial for dry eye d…
8011×5242
www.ophthalmologytimes.com
Clearside Biomedical unveils positive topline results from ODYSSEY Pha…
1200×800
www.ophthalmologytimes.com
LumiThera’s Valeda Light Delivery System receives marketing authori…
1200×667
www.ophthalmologytimes.com
enVista Envy by Bausch + Lomb approved by Health Canada
1272×708
www.ophthalmologytimes.com
enVista Envy by Bausch + Lomb approved by Health Canada
1920×1080
www.ophthalmologytimes.com
Johnson & Johnson launches TECNIS Odyssey IOL in US
1200×800
www.ophthalmologytimes.com
Dean McGee Eye Institute continues tradition of leadershi…
1280×720
www.ophthalmologytimes.com
Aviceda begins part 2 of Phase II/III trial for geographic atrophy
1916×1033
www.ophthalmologytimes.com
Aviceda begins part 2 of Phase II/III trial for geographic atrophy
1920×1080
www.ophthalmologytimes.com
Aviceda begins part 2 of Phase II/III trial for geographic atrophy
1680×939
www.ophthalmologytimes.com
Aviceda begins part 2 of Phase II/III trial for geographic atrophy
1280×720
www.ophthalmologytimes.com
Advancements in ophthalmology: A comprehensive look at the FDA's 2023 approvals
1280×720
www.ophthalmologytimes.com
Advancements in ophthalmology: A comprehensive look at the FDA's 2023 approvals
1200×900
www.ophthalmologytimes.com
Dry eye paradise: FDA green-lights Miebo as first and only eye drop approved for the condit…
1280×720
www.ophthalmologytimes.com
FDA approves pilocarpine hydrochloride ophthalmic solution for treatment of presbyopia
1280×720
www.ophthalmologytimes.com
FDA approves pilocarpine hydrochloride ophthalmic solution for treatment of presbyopia
1200×718
www.ophthalmologytimes.com
FDA approves pilocarpine hydrochloride ophthalmic solution for treatment of pres…
2001×2001
www.ophthalmologytimes.com
Intense pulsed light for treatment of dry eye d…
1920×1080
www.ophthalmologytimes.com
Alert: Alcon voluntarily recalls Systane Ultra PF lot due to potential fungal contamination
1280×720
www.ophthalmologytimes.com
Extended depth-of-focus IOL provides better tolerance of ATR astigmatism
1200×675
www.ophthalmologytimes.com
FDA issues revised draft guidance on quality considerations for ophthalmic drugs
某些结果已被隐藏，因为你可能无法访问这些结果。
显示无法访问的结果
报告不当内容
请选择下列任一选项。
无关
低俗内容
成人
儿童性侵犯
反馈
反馈
